Zydus Insists Mitsubishi Doesn't Deserve Diabetes Patents
Zydus Pharmaceuticals punctuated the six-day trial in its bid to bring generic diabetes drugs to market by filing a 100-page, post-trial brief doubling down on its claim that Mitsubishi Tanabe Pharma Corp. is engaging...To view the full article, register now.
Already a subscriber? Click here to view full article